Perrigo Company plc
PRGOPerrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How PRGO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
pseudoephedrine hydrochloride 30 mg tablets | Phase 3 | Nasal Congestion Associated With the Common Cold | - | - |
Frequently asked questions
What is in Perrigo Company plc's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Perrigo Company plc's (PRGO) pipeline across Phase 3. Its lead program is pseudoephedrine hydrochloride 30 mg tablets (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Perrigo Company plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Perrigo Company plc (PRGO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PRGO biotech catalysts?→
Add PRGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Perrigo Company plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.